Capricor Therapeutics (CAPR) recently drew investor attention after presenting new clinical data on its Duchenne muscular dystrophy therapy deramiocel and confirming an upcoming PDUFA decision date with regulators.

Those clinical updates and the confirmed PDUFA date come as momentum has been strong, with a 24.36% 30 day share price return and a very large 1 year total shareholder return that has built on multi year gains.

If you are looking for more early stage healthcare names tied to medical breakthroughs, this is a good moment to widen your search using our 36 healthcare AI stocks

With Capricor Therapeutics now valued around US$1.85b, a recent share price of US$32.11 and analyst targets sitting higher, the key question is simple: is there still an opportunity here or is future growth already priced in?

Most Popular Narrative: 36.8% Undervalued

Capricor Therapeutics' most followed valuation narrative places fair value at about $50.80 per share, well above the recent $32.11 close, with that gap built on aggressive growth and profitability assumptions.

The analysts have a consensus price target of $20.6 for Capricor Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $12.0.

Want to see what justifies a fair value well above the current price? The narrative leans on rapid revenue expansion, a margin flip to profitability, and a rich future earnings multiple. Curious which specific growth path and profitability profile need to line up to support that outcome? The full story sits inside those projections.

Result: Fair Value of $50.80 (UNDERVALUED)

However, there are still clear pressure points, including Capricor’s reliance on Deramiocel and rising R&D costs that could extend timelines or increase dilution risk.

Next Steps

With sentiment running hot and both risks and rewards in play, this is the moment to look through the numbers yourself and decide where you stand, starting with the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you only focus on one stock, you could miss other compelling setups, so consider widening your watchlist now using screeners that surface clear, data driven opportunities.

• Target reliable cash generators and income potential by scanning companies that pass the 13 dividend fortresses.
• Hunt for companies where price and fundamentals look out of sync by running the screener containing 25 high quality undiscovered gems.
• Prioritise resilience by checking which names stand out in the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.